ADVISORY COMMITTEE ON IMMUNIZATION PRACTICES VACCINES FOR CHILDREN PROGRAM VACCINES TO PREVENT PNEUMOCOCCAL DISEASE

Resolution No. 02/10-1
ADVISORY COMMITTEE ON IMMUNIZATION PRACTICES VACCINES FOR CHILDREN PROGRAM VACCINES TO PREVENT PNEUMOCOCCAL DISEASE

The purpose of this resolution is to reflect the replacement of the seven valent pneumococcal conjugate vaccine (PCV7) with the thirteen valent conjugate vaccine (PCV13). . Note: Until the transition between seven valent pneumococcal conjugate vaccine (PCV7) and thirteen valent pneumococcal conjugate vaccine (PCV13) is complete and providers have sufficient supplies of thirteen valent pneumococcal conjugate vaccine in their offices to meet demand among VFC eligible children, the VFC program will continue to include seven valent pneumococcal conjugate vaccine and the schedule provided in VFC resolution 2/09-1 should be followed for administration of PCV7 during that time. VFC resolution 2/09-1 is repealed and replaced by the following: A. Pneumococcal Conjugate Vaccine to Prevent Pneumococcal Disease Eligible groups • All children at least six weeks through 59 months of age and children 60 through 71 months with certain underlying medical conditions listed in the table below. • Children 6 through 18 years of age who are at increased risk for invasive pneumococcoal disease because of sickle cell disease, HIV-infection, or other immunocompromising condition.
PDF, 4 pages:
http://www.cdc.gov/vaccines/programs/vfc/downloads/resolutions/0210-pneumo-508.pdf